BRPI0516350A - fusion protein, isolated nucleic acid, vector, host cell, method of producing a polypeptide, composition, method of modulating an immunoresponse in an individual, method for increasing the half life of a recombinant protein in an individual, and method for increasing the efficacy of a recombinant protein in an individual and method of applying a therapeutic protein to a target site in an individual - Google Patents
fusion protein, isolated nucleic acid, vector, host cell, method of producing a polypeptide, composition, method of modulating an immunoresponse in an individual, method for increasing the half life of a recombinant protein in an individual, and method for increasing the efficacy of a recombinant protein in an individual and method of applying a therapeutic protein to a target site in an individualInfo
- Publication number
- BRPI0516350A BRPI0516350A BRPI0516350-1A BRPI0516350A BRPI0516350A BR PI0516350 A BRPI0516350 A BR PI0516350A BR PI0516350 A BRPI0516350 A BR PI0516350A BR PI0516350 A BRPI0516350 A BR PI0516350A
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- protein
- fusion protein
- increasing
- recombinant protein
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 6
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 102000039446 nucleic acids Human genes 0.000 title abstract 4
- 108020004707 nucleic acids Proteins 0.000 title abstract 4
- 150000007523 nucleic acids Chemical class 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 239000013598 vector Substances 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title 2
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 abstract 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 abstract 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 abstract 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 102000003675 cytokine receptors Human genes 0.000 abstract 1
- 108010057085 cytokine receptors Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
PROTEìNA DE FUSãO, áCIDO NUCLéICO ISOLADO, VETOR, CéLULA HOSPEDEIRA, MéTODO DE PRODUçãO DE UM POLIPEPTìDIO, COMPOSIçãO, MéTODO DE MODULAçãO DE UMA IMUNORESPOSTA EM UM INDIVìDUO, MéTODO PARA AUMENTAR A MEIA VIDA DE UMA PROTEìNA RECOMBINANTE EM UM INDIVìDUO, MéTODO PARA AUMENTAR A EFICáCIA DE UMA PROTEìNA RECOMBINANTE EM UM INDIVìDUO E MéTODO DE APLICAçãO DE UMA PROTEìNA TERAPêUTICA A UM SìTIO ALVO EM UM INDIVìDUO. Trata-se de uma proteína de fusão que contém um primeiro segmento que fica localizado no terminal amino da proteína de fusão e se liga especificamente a e neutraliza uma primeira citocina ou fator de crescimento; e um segundo segmento que fica localizado no terminal carboxila da proteína de fusão e se liga especificamente a um segundo receptor de citocina que é normalmente rico em sítios de doenças tais como o sítio inflamatório rico em receptor IL-l. Além disso, o dito segundo segmento é normalmente o antagonista do receptor, tal como o antagonista do receptor IL-l e seus análogos equivalentes funcionais. Também são descritos ácidos nucléicos que codificam a proteína de fusão, os vetores e as células hospedeiras que têm os ácidos nucléicos, e a composição e os métodos relacionados às doenças inflamatórias alvo e às indicações que co-existiram com a inflamação.FUSION PROTEIN, NUCLEIC ACID ISOLATED, VECTOR, HOST CELL, METHOD OF PRODUCTION OF A POLYPETID, COMPOSITION, METHOD OF MODULATION OF AN IMMUNDS INTO A VIDEO AID FOR A VEHICLE EFFICACY OF RECOMBINATING PROTEIN IN AN INDIVIDUAL AND METHOD OF APPLYING THERAPEUTIC PROTEIN TO A TARGET SITE IN AN INDIVIDUAL. It is a fusion protein that contains a first segment that is located at the amino terminus of the fusion protein and specifically binds to and neutralizes a first cytokine or growth factor; and a second segment that is located at the carboxy terminus of the fusion protein and specifically binds to a second cytokine receptor that is normally rich in disease sites such as the IL-1 receptor rich inflammatory site. Furthermore, said second segment is usually the receptor antagonist, such as the IL-1 receptor antagonist and its equivalent functional analogs. Nucleic acids encoding the fusion protein, vectors and host cells bearing the nucleic acids, and the composition and methods related to the target inflammatory diseases and indications that coexisted with inflammation are also described.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61847604P | 2004-10-12 | 2004-10-12 | |
| US62899404P | 2004-11-17 | 2004-11-17 | |
| US65073405P | 2005-02-01 | 2005-02-01 | |
| PCT/US2005/012194 WO2006043972A1 (en) | 2004-10-12 | 2005-04-08 | Chimeric protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0516350A true BRPI0516350A (en) | 2008-09-02 |
Family
ID=39445826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0516350-1A BRPI0516350A (en) | 2004-10-12 | 2005-04-08 | fusion protein, isolated nucleic acid, vector, host cell, method of producing a polypeptide, composition, method of modulating an immunoresponse in an individual, method for increasing the half life of a recombinant protein in an individual, and method for increasing the efficacy of a recombinant protein in an individual and method of applying a therapeutic protein to a target site in an individual |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1799246A4 (en) |
| JP (1) | JP2008515970A (en) |
| KR (1) | KR20080022539A (en) |
| AU (1) | AU2005296277A1 (en) |
| BR (1) | BRPI0516350A (en) |
| CA (1) | CA2583937A1 (en) |
| IL (1) | IL182497A0 (en) |
| NZ (1) | NZ554481A (en) |
| WO (1) | WO2006043972A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10259860B2 (en) | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
| HUE024903T2 (en) * | 2007-12-26 | 2016-02-29 | Xencor Inc | Fc variants with altered binding to fcrn |
| US10106587B2 (en) | 2008-02-27 | 2018-10-23 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
| US8753690B2 (en) | 2008-02-27 | 2014-06-17 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
| WO2009149205A2 (en) * | 2008-06-03 | 2009-12-10 | Neurotech Usa, Inc. | Cell lines that secrete soluble vegf receptors and uses thereof |
| NZ590668A (en) * | 2008-07-02 | 2012-12-21 | Emergent Product Dev Seattle | TNF-alpha ANTAGONIST MULTI-TARGET BINDING PROTEINS |
| EP2310508A1 (en) * | 2008-07-02 | 2011-04-20 | Emergent Product Development Seattle, LLC | Tgf-b antagonist multi-target binding proteins |
| US8722860B2 (en) | 2009-04-16 | 2014-05-13 | Abbvie Biotherapeutics Inc. | Anti-TNF-α antibodies and their uses |
| EP2443150B1 (en) | 2009-06-17 | 2015-01-21 | AbbVie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
| AU2010292486B2 (en) | 2009-08-27 | 2014-08-07 | Biomet Biologics, Llc | Implantable device for production of interleukin-1 receptor antagonist |
| KR101004363B1 (en) * | 2010-03-19 | 2010-12-28 | 가톨릭대학교 산학협력단 | TNF-α AND IL-21 COUPLED ANTAGONIST FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASES |
| KR101004362B1 (en) * | 2010-03-19 | 2010-12-28 | 가톨릭대학교 산학협력단 | TNF-α AND TWEAK COUPLED ANTAGONIST FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASES |
| US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
| US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
| US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
| US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
| US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
| US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
| US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
| US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
| US9833474B2 (en) | 2013-11-26 | 2017-12-05 | Biomet Biologies, LLC | Methods of mediating macrophage phenotypes |
| US10441635B2 (en) | 2014-11-10 | 2019-10-15 | Biomet Biologics, Llc | Methods of treating pain using protein solutions |
| US9763800B2 (en) | 2015-03-18 | 2017-09-19 | Biomet C. V. | Implant configured for hammertoe and small bone fixation |
| CN113402583B (en) * | 2021-06-19 | 2023-03-21 | 江西农业大学 | QGK tripeptide and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541610B1 (en) * | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
| EP0575545B1 (en) * | 1991-03-15 | 2003-05-21 | Amgen Inc. | Pegylation of polypeptides |
| US6548634B1 (en) * | 1998-09-30 | 2003-04-15 | Chiron Corporation | Synthetic peptides having FGF receptor affinity |
| EP1781684A4 (en) * | 2004-08-25 | 2008-05-21 | Amprotein Corp | A novel chimeric polypeptide and use thereof |
-
2005
- 2005-04-08 JP JP2007536675A patent/JP2008515970A/en active Pending
- 2005-04-08 EP EP05737667A patent/EP1799246A4/en not_active Withdrawn
- 2005-04-08 KR KR1020077008321A patent/KR20080022539A/en not_active Application Discontinuation
- 2005-04-08 BR BRPI0516350-1A patent/BRPI0516350A/en not_active IP Right Cessation
- 2005-04-08 NZ NZ554481A patent/NZ554481A/en unknown
- 2005-04-08 AU AU2005296277A patent/AU2005296277A1/en not_active Abandoned
- 2005-04-08 WO PCT/US2005/012194 patent/WO2006043972A1/en active Application Filing
- 2005-04-08 CA CA002583937A patent/CA2583937A1/en not_active Abandoned
-
2007
- 2007-04-12 IL IL182497A patent/IL182497A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005296277A1 (en) | 2006-04-27 |
| EP1799246A1 (en) | 2007-06-27 |
| IL182497A0 (en) | 2007-09-20 |
| WO2006043972A1 (en) | 2006-04-27 |
| WO2006043972A8 (en) | 2006-06-15 |
| JP2008515970A (en) | 2008-05-15 |
| EP1799246A4 (en) | 2009-08-12 |
| CA2583937A1 (en) | 2006-04-27 |
| KR20080022539A (en) | 2008-03-11 |
| NZ554481A (en) | 2010-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0516350A (en) | fusion protein, isolated nucleic acid, vector, host cell, method of producing a polypeptide, composition, method of modulating an immunoresponse in an individual, method for increasing the half life of a recombinant protein in an individual, and method for increasing the efficacy of a recombinant protein in an individual and method of applying a therapeutic protein to a target site in an individual | |
| CL2011003121A1 (en) | Fusion protein comprising a growth hormone (gh) sequence, linked to an extended recombinant polypeptide (xten) comprising at least 200 amino acids, lacks t cell epitopes and residues g, a, s, t, e and p add up to more 90%; nucleic acid, vector and cell; Method of production; pharmaceutical composition and use. | |
| JP5002603B2 (en) | Novel peptides and uses thereof | |
| PE20191033A1 (en) | HETERODIMERIC FC FUSION PROTEINS IL 15 / IL 15R (alpha) | |
| HRP20130194T1 (en) | Immunosuppressive polypeptides and nucleic acids | |
| PE20120570A1 (en) | DIFFERENTIATION OF MESENCHYMAL STEM CELLS | |
| PE20190352A1 (en) | GDF 15 FUSION PROTEINS AND USES OF THEM | |
| MX2009012609A (en) | Compositions and methods for producing bioactive fusion proteins. | |
| BR112012009854B8 (en) | recombinant isolated antigen binding protein that binds IL-23, pharmaceutical composition, isolated recombinant nucleic acid molecule, recombinant vector, method of making said binding protein and use thereof | |
| MX362028B (en) | Extended recombinant polypeptides and compositions comprising same. | |
| NZ754961A (en) | Growth differentiation factor 15 (gdf-15) constructs | |
| BR112012006501A8 (en) | POLYPEPTIDES AND USES THEREOF | |
| AR066885A1 (en) | NATURAL FUSION PROTEINS | |
| BR112019002238A2 (en) | manipulated polypeptide and cell, and fermentation method. | |
| ATE517118T1 (en) | BIS-MET HISTONES | |
| WO2006032923A3 (en) | Inhibitors of protein kinase a anchoring | |
| BR112017022076A2 (en) | Mesothelin-variant III fusions of epidermal growth factor receptor and methods of use thereof | |
| BRPI0517362A (en) | polypeptide, purified nucleic acid molecule, vector, host cell, antibody, in vitro methods for diagnosing a disease in a patient, pharmaceutical composition, vaccine composition, use of a polypeptide, fusion protein, and method for protein production | |
| Nonaka et al. | Domain 36 of tropoelastin in elastic fiber formation | |
| EA201291416A1 (en) | PEPTIDES ASSOCIATED WITH THE RECEPTOR OF INSULIN-LIKE GROWTH FACTOR 1 | |
| CO2023000048A2 (en) | cytokine conjugates | |
| ATE510008T1 (en) | ANTI-INFLAMMATORY PEPTIDES | |
| CA2716392A1 (en) | Mntf peptide compositions and methods of use | |
| KR102404717B1 (en) | AB6 family designer ligands from the TGF-beta superfamily | |
| BRPI0807786A2 (en) | ERYTHROPOIETIN FUSION PROTEIN, METHOD FOR PREPARING A RECOMBINANT EPO-FUSION PROTEIN, USE OF A FUSION PROTEIN, AND PHARMACEUTICAL COMPOSITION. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 3A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |